The core purpose of NVG treatment is to reduce the IOP to within the normal range, improve retina ischemia, and preserve visual function.[3,11] Thus, anti-VEGF treatment is an important strategy for NVG management, as it can neutralize VEGF, leading to the regression of neovascularization within the iris and anterior chamber,[3,11,12] and reduce intraoperative bleeding, thereby improving the success rate of glaucoma surgery.[3] Moreover, anti-VEGF treatment could create an effective opportunity for PRP treatment. Here, VEGFA is linked to ischemia.